TapewireFind a company

person · Reporting owner

Kirn David

Disclosed activity across 1 company

Tapewire entity
20739
SEC CIK
0001834021

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
4D Molecular Therapeutics, Inc.FDMT · Entity 2419Director · See RemarksOctober 05, 2026October 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

4D Molecular Therapeutics, Inc.

Report date October 05, 2026 · Filed October 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect709,153 Ending reported balance After 2026-10-05 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-05 · Sale · Disposed 58,061 · Balance 709,425

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2: The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Row 2 · 2026-10-05 · Sale · Disposed 272 · Balance 709,153

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F3: The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2: The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 05, 2026 Filed Oct 7, 2026 21:11 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 272 $13.61 $3,702.03
Disclosure

SEC source: 0001193125-26-417068 · ownership.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 709,153

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F3 · price: The transaction was executed in multiple trades in prices ranging from $13.61 to $13.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
October 05, 2026 Filed Oct 7, 2026 21:11 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 58,061 $12.92 $750,235.21
Disclosure

SEC source: 0001193125-26-417068 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 709,425

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2 · price: The transaction was executed in multiple trades in prices ranging from $12.61 to $13.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
September 14, 2026 Filed Sep 16, 2026 21:13 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 58,333 $13.90 $811,003.70
Disclosure

SEC source: 0001193125-26-393243 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 767,486

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2 · price: The transaction was executed in multiple trades in prices ranging from $13.43 to $14.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 19, 2026 Filed Aug 21, 2026 20:06 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $4.14 $0.00
Disclosure

SEC source: 0001193125-26-361096 · ownership.xml · derivative · entry 4

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 217,500

Underlying: Common Stock · 50,000 shares

Expires 2035-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
August 19, 2026 Filed Aug 21, 2026 20:06 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 25,927 $16.42 $425,651.34
Disclosure

SEC source: 0001193125-26-361096 · ownership.xml · nonDerivative · entry 3

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 825,819

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F3 · price: The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 19, 2026 Filed Aug 21, 2026 20:06 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 43,149 $15.36 $662,621.93
Disclosure

SEC source: 0001193125-26-361096 · ownership.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 851,746

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2 · price: The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 19, 2026 Filed Aug 21, 2026 20:06 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 50,000 $4.14 $207,000.00
Disclosure

SEC source: 0001193125-26-361096 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 894,895

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

Read SEC document
August 04, 2026 Filed Aug 5, 2026 20:10 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 26,842 $10.23 $274,596.34
Disclosure

SEC source: 0001193125-26-335115 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 844,895

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2 · price: The transaction was executed in multiple trades in prices ranging from $10.07 to $10.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 03, 2026 Filed Aug 4, 2026 20:45 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 12,415 $10.05 $124,722.33
Disclosure

SEC source: 0001193125-26-333014 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 871,737

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2 · price: The transaction was executed in multiple trades in prices ranging from $10.00 to $10.1250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
July 10, 2026 Filed Jul 14, 2026 21:04 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 442 $12.84 $5,673.29
Disclosure

SEC source: 0001834021-26-000004 · ownership.xml · nonDerivative · entry 3

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 884,152

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F4 · price: The transaction was executed in multiple trades in prices ranging from $12.82 to $12.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
July 10, 2026 Filed Jul 14, 2026 21:04 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 15,283 $12.01 $183,559.53
Disclosure

SEC source: 0001834021-26-000004 · ownership.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 884,594

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F3 · price: The transaction was executed in multiple trades in prices ranging from $11.575 to $12.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
July 09, 2026 Filed Jul 14, 2026 21:04 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 42,608 $12.87 $548,177.48
Disclosure

SEC source: 0001834021-26-000004 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 899,877

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2 · price: The transaction was executed in multiple trades in prices ranging from $12.68 to $13.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
June 22, 2026 Filed Jun 23, 2026 20:19 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 114,746 $10.47 $1,200,851.31
Disclosure

SEC source: 0001834021-26-000002 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 942,485

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2 · price: The transaction was executed in multiple trades in prices ranging from $10.00 to $10.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 20:48 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 1,922 $10.02 $19,257.86
Disclosure

SEC source: 0001193125-26-253740 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,057,231

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

F2 · price: The transaction was executed in multiple trades in prices ranging from $10.00 to $10.055, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
March 25, 2026 Filed Mar 27, 2026 20:30 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 GrantStock Option (Right to Buy) · Derivative 750,000 $0.00 Strike: $9.88 $0.00
Disclosure

SEC source: 0001193125-26-129156 · ownership.xml · derivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750,000

Underlying: Common Stock · 750,000 shares

Expires 2036-03-24

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
March 06, 2025 Filed Mar 10, 2025 23:58 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 GrantStock Option (Right to Buy) · Derivative 267,500 $0.00 Strike: $4.14 $0.00
Disclosure

SEC source: 0000950170-25-036688 · ownership.xml · derivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 267,500

Underlying: Common Stock · 267,500 shares

Expires 2035-03-05

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 21:46 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 1,270 $0.00 Strike: $15.78 $0.00
Disclosure

SEC source: 0000950170-24-083303 · ownership.xml · derivative · entry 5

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 148,730

Underlying: Common Stock · 1,270 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.

F4 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 21:46 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 11,653 $0.00 Strike: $14.42 $0.00
Disclosure

SEC source: 0000950170-24-083303 · ownership.xml · derivative · entry 4

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 565,417

Underlying: Common Stock · 11,653 shares

Expires 2033-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 21:46 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 12,923 $22.49 $290,598.21
Disclosure

SEC source: 0000950170-24-083303 · ownership.xml · nonDerivative · entry 3

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,059,153

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.

F2 · price: The transaction was executed in multiple trades in prices ranging from $22.05 to $23.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 21:46 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 1,270 $15.78 $20,040.60
Disclosure

SEC source: 0000950170-24-083303 · ownership.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,072,076

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.

Read SEC document
July 10, 2024 Filed Jul 12, 2024 21:46 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 11,653 $14.42 $168,036.26
Disclosure

SEC source: 0000950170-24-083303 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,070,806

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 21:07 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionStock Option (Right To Buy) · Derivative 12,930 $0.00 Strike: $14.42 $0.00
Disclosure

SEC source: 0000950170-24-077944 · ownership.xml · derivative · entry 3

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 577,070

Underlying: Common Stock · 12,930 shares

Expires 2033-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 21:07 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 12,930 $23.10 $298,711.45
Disclosure

SEC source: 0000950170-24-077944 · ownership.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,059,153

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.

F2 · price: The transaction was executed in multiple trades in prices ranging from $22.69 to $23.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 21:07 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 Exercise / conversionCommon Stock 12,930 $14.42 $186,450.60
Disclosure

SEC source: 0000950170-24-077944 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,072,083

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 21, 2024.

Read SEC document
February 08, 2024 Filed Feb 13, 2024 01:22 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 92,001 $27.13 $2,495,821.53
Disclosure

SEC source: 0000950170-24-014091 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,059,153

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.

F2 · price: The transaction was executed in multiple trades in prices ranging from $26.75 to $27.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 21:59 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 5,696 $18.41 $104,851.40
Disclosure

SEC source: 0000950170-24-007477 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,151,154

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.

F2 · price: The transaction was executed in multiple trades in prices ranging from $18.06 to $18.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 05, 2024 Filed Jan 8, 2024 21:19 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 133 $20.11 $2,673.97
Disclosure

SEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 5

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,156,850

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.

F6 · price: The transaction was executed in multiple trades in prices ranging from $20.09 to $20.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 05, 2024 Filed Jan 8, 2024 21:19 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 28,104 $19.56 $549,804.17
Disclosure

SEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 4

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,156,983

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.

F5 · price: The transaction was executed in multiple trades in prices ranging from $19.085 to $20.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 04, 2024 Filed Jan 8, 2024 21:19 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 40,732 $20.31 $827,201.75
Disclosure

SEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 3

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,185,087

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.

F4 · price: The transaction was executed in multiple trades in prices ranging from $20.02 to $20.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 18, 2023 Filed Jan 8, 2024 21:19 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 4,702 $18.13 $85,242.56
Disclosure

SEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,225,819

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.

F3 · price: The transaction was executed in multiple trades in prices ranging from $17.77 to $18.525, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 15, 2023 Filed Jan 8, 2024 21:19 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 28,632 $17.27 $494,431.69
Disclosure

SEC source: 0000950170-24-002945 · ownership.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,230,521

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.

F2 · price: The transaction was executed in multiple trades in prices ranging from $17.00 to $17.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 11, 2023 Filed Dec 13, 2023 21:05 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 GrantStock Option (Right to Buy) · Derivative 590,000 $0.00 Strike: $14.42 $0.00
Disclosure

SEC source: 0000950170-23-070013 · ownership.xml · derivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 590,000

Underlying: Common Stock · 590,000 shares

Expires 2033-12-10

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Read SEC document
May 02, 2023 Filed May 5, 2023 00:09 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 GiftCommon Stock 600,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-023022 · form4.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Family Trusts

Disclosed balance after: 600,000

F1 · kind: Reflects gifts of shares by the Reporting Person to irrevocable trusts established for the benefit of the Reporting Person's children. The Goldman Sachs Trust Company of Delaware is the Trustee of such trusts.

Read SEC document
May 02, 2023 Filed May 5, 2023 00:09 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 GiftCommon Stock 600,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-023022 · form4.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,259,153

Read SEC document
February 22, 2023 Filed Feb 24, 2023 00:56 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 16,449 $20.22 $332,664.58
Disclosure

SEC source: 0001567619-23-003706 · doc1.xml · nonDerivative · entry 3

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,859,153

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The transaction was executed in multiple trades in prices ranging from $19.96 to $20.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
February 21, 2023 Filed Feb 24, 2023 00:56 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 907 $21.49 $19,491.16
Disclosure

SEC source: 0001567619-23-003706 · doc1.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,875,602

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The transaction was executed in multiple trades in prices ranging from $21.40 to $21.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
February 21, 2023 Filed Feb 24, 2023 00:56 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 17,090 $20.93 $357,717.63
Disclosure

SEC source: 0001567619-23-003706 · doc1.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,876,509

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The transaction was executed in multiple trades in prices ranging from $20.35 to $21.305, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
February 10, 2023 Filed Feb 15, 2023 01:24 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 GrantStock Option (Right to Buy) · Derivative 222,000 $0.00 Strike: $20.24 $0.00
Disclosure

SEC source: 0001567619-23-003008 · doc1.xml · derivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,000

Underlying: Common Stock · 222,000 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company

Read SEC document
January 20, 2023 Filed Jan 24, 2023 00:57 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 8,625 $20.19 $174,126.68
Disclosure

SEC source: 0001567619-23-001163 · doc1.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,893,599

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The transaction was executed in multiple trades in prices ranging from $20.01 to $20.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 19, 2023 Filed Jan 24, 2023 00:57 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 10,899 $20.03 $218,347.30
Disclosure

SEC source: 0001567619-23-001163 · doc1.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,902,224

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The transaction was executed in multiple trades in prices ranging from $19.83 to $20.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 16, 2022 Filed Dec 19, 2022 22:56 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 26,349 $23.39 $616,205.62
Disclosure

SEC source: 0001567619-22-021815 · doc1.xml · nonDerivative · entry 4

Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,913,123

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The transaction was executed in multiple trades in prices ranging from $23.19 to $23.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 16, 2022 Filed Dec 19, 2022 22:56 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 27,595 $22.66 $625,371.69
Disclosure

SEC source: 0001567619-22-021815 · doc1.xml · nonDerivative · entry 3

Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,939,472

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The transaction was executed in multiple trades in prices ranging from $22.18 to $23.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 15, 2022 Filed Dec 19, 2022 22:56 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 1,500 $24.13 $36,199.05
Disclosure

SEC source: 0001567619-22-021815 · doc1.xml · nonDerivative · entry 2

Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,967,067

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The transaction was executed in multiple trades in prices ranging from $24.07 to $24.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 15, 2022 Filed Dec 19, 2022 22:56 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 SaleCommon Stock 31,433 $23.56 $740,567.77
Disclosure

SEC source: 0001567619-22-021815 · doc1.xml · nonDerivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,968,567

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The transaction was executed in multiple trades in prices ranging from $23.04 to $24.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
February 01, 2022 Filed Feb 3, 2022 22:40 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 GrantStock Option (Right to Buy) · Derivative 150,000 $0.00 Strike: $15.78 $0.00
Disclosure

SEC source: 0001567619-22-002466 · doc1.xml · derivative · entry 2

Kirn David · CIK 0001834021 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company.

Read SEC document
March 08, 2021 Filed Mar 10, 2021 21:05 UTC 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 GrantStock Option (Right to Buy) · Derivative 150,000 $0.00 Strike: $41.66 $0.00
Disclosure

SEC source: 0001567619-21-005967 · doc1.xml · derivative · entry 1

Kirn David · CIK 0001834021 · Director · See Remarks · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2031-03-07

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 8, 2021 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.